Abstract
Acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) are the two most common leukemias of the immune system. Each of these diseases is characterized by diverse somatic driving aberrations of significant prognostic significance, and these are used for risk stratification and adjustment of therapy. Recent advances in the science of immunology have resulted in dramatic development of new and effective therapies for patients with these malignancies.
| Original language | English |
|---|---|
| Title of host publication | Clinical Immunology |
| Subtitle of host publication | Principles and Practice, Sixth Edition |
| Publisher | Elsevier |
| Pages | 984-999 |
| Number of pages | 16 |
| ISBN (Electronic) | 9780702081651 |
| ISBN (Print) | 9780702081668 |
| DOIs | |
| State | Published - 1 Jan 2022 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2023 Elsevier Ltd. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Acute lymphoblastic leukemia
- B-cell receptor signaling
- chronic lymphocytic leukemia
- clonal diversity
- immunotherapy
Fingerprint
Dive into the research topics of 'Lymphoid Leukemias'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver